October 4th, 2011 by MotherJonesRN in Opinion
1 Comment »
Here is Clara Barton, posing with a new class of graduate nurses who received their nursing education through a correspondence course offered by the Chautauqua School of Nursing. Did you know that some of Clara Barton’s contemporaries did not view her as a legitimate nursing leader because she supported alternative ways of getting a nursing education? It’s kind of ironic that many nursing leaders back then didn’t view the founder of the American Red Cross as an equal. Some things never change.
It’s an old discussion. Are nurses with an advanced degree better nurses? Do they make better leaders and does getting a degree elevate the profession? My blog mother, Kim McAllister, from Emergiblog brought my attention to an article that appears at HealthLeadersMedia.com. The article contains Read more »
*This blog post was originally published at Nurse Ratched's Place*
October 4th, 2011 by GruntDoc in News
2 Comments »
This underestimates the increased cost by a huge factor…
Remember how Obama recently waived new ozone regulations at the EPA because they were too costly? Well, it seems that the Obama administration would rather make people with Asthma cough up money than let them make a surely inconsequential contribution to depleting the ozone layer:
Asthma patients who rely on over-the-counter inhalers will need to switch to prescription-only alternatives as part of the federal government’s latest attempt to protect the Earth’s atmosphere.
…But the switch to a greener inhaler will cost consumers more. Epinephrine inhalers are available via online retailers for Read more »
*This blog post was originally published at GruntDoc*
October 3rd, 2011 by Harriet Hall, M.D. in Research
No Comments »
There has been an ongoing debate about placebos on SBM, both in the articles and in the comments. What does it mean that a treatment has been shown to be “no better than placebo?” If our goal is for patients to feel better and they feel better with placebos, why not prescribe them? Do placebos actually do anything useful? What can science tell us about why a patient might report diminished pain after taking an inert sugar pill? The subject is complex and prone to misconceptions. A recent podcast interview offers a breakthrough in understanding.
On her Brain Science Podcast Dr. Ginger Campbell interviewed Dr. Fabrizio Benedetti, a physician and clinical neurophysiologist who is one of the world’s leading researchers on the neurobiology of placebos. A transcript of the interview [PDF] is available on her website for those who prefer reading to listening. The information Dr. Benedetti presents and the expanded remarks by Dr. Campbell after the interview go a long way towards explaining the placebo phenomenon and its consequences for clinical medicine. Dr. Campbell also includes a handy list of references. I’ll try to provide a summary of the main points, but I recommend reading or listening to the original.
A common misconception is that Read more »
*This blog post was originally published at Science-Based Medicine*
October 3rd, 2011 by Medgadget in News
No Comments »
Sleep tracking company Zeo has announced today that they’ll soon be selling a mobile version of their product, compatible with both iOS and Android. The company previously only offered what amounted to a base-station clock with a sleep monitoring headband. Together they tracked your sleep patterns, including Light, Deep, and REM, but in the process the data got a bit trapped in their clock. To upload sleep data to the web for easier analysis, users had to pull an SD card out of the clock, plug it to a computer, and complete the upload. This step presented a pretty high barrier to learning about your personal sleep.
The mobile version solves this Read more »
*This blog post was originally published at Medgadget*
October 3rd, 2011 by DrWes in Health Policy, Opinion
No Comments »
I had a patient with non-valvular atrial flutter denied dabigatran (Pradaxa®) by their insurer recently. The patient had diabetes, hypertension and has had a heck of a time maintaining therapeutic blood thinning levels (prothrombin times).
But those are the rules, you see. Only patients with non-rheumatic atrial fibrillation can get dabigatran, I was told. Dabigatran was never approved for atrial flutter, only atrial fibrillation. Never mind the stroke risk in non-rheumatic atrial flutter, like atrial fibrillation, has been found to be significant.
For my patient, dabigatran would have been the perfect solution.
But increasingly I’m finding the patient is not mine, they’re Read more »
*This blog post was originally published at Dr. Wes*
